Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RET |
Variant | C634Y |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | RET C634Y lies within the cysteine-rich region of the Ret protein (PMID: 9230192). C634Y results in formation of covalent Ret homodimers, increased Ret phosphorylation and activation of downstream signaling, resistance to apoptosis, and is transforming in cell culture (PMID: 9230192, PMID: 10919641). |
Associated Drug Resistance | |
Category Variants Paths |
RET mutant RET act mut RET C634Y RET mutant RET C634X RET C634Y |
Transcript | NM_020975.6 |
gDNA | chr10:g.43114501G>A |
cDNA | c.1901G>A |
Protein | p.C634Y |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406783.1 | chr10:g.43123796G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_020975.6 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_020630 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_020630.7 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_001406759.1 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_001406743.1 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_001406786.1 | chr10:g.43123796G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_001406744.1 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_020975.5 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_020975 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_020630.5 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
NM_001406760.1 | chr10:g.43114501G>A | c.1901G>A | p.C634Y | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C634Y | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells harboring RET C634Y in culture (PMID: 23526464). | 23526464 |
RET C634Y | Advanced Solid Tumor | sensitive | HG-6-63-01 | Preclinical | Actionable | In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350). | 26046350 |
RET C634Y | Advanced Solid Tumor | sensitive | XMD15-44 | Preclinical | Actionable | In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350). | 26046350 |
RET C634Y | Advanced Solid Tumor | sensitive | ALW-II-41-27 | Preclinical - Cell culture | Actionable | In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350). | 26046350 |
RET C634Y | medullary thyroid carcinoma | predicted - sensitive | Sorafenib | Case Reports/Case Series | Actionable | In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634Y (PMID: 20368568; NCT00390325). | 20368568 |